Project Grant R01CA286612
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$958K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will provide $135,774 to The Leland Stanford Junior University to conduct research on "Reinvigorating the Overdominant Model of Tumor Suppression." The research aims to systematically measure the overdominant effect of tumor suppressor genes in vivo, investigate the molecular mechanisms of overdominant tumor suppression, and quantify the prevalence of overdominance in lung...
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This $135,594 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award aims to develop novel pharmacological approaches to rewire oncogenic gene expression and induce apoptosis in cancer cells, with a focus on aggressive leukemias driven by mixed-lineage leukemia (MLL) gene translocations. The research will involve organic synthesis, pharmacological assays, chromatin mechanism studies, cellular model...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, will provide $131,099 to The Leland Stanford Junior University (Stanford University) from July 1, 2025 to June 30, 2027. The award will fund research to investigate the multilevel impacts of obesity-related factors, from molecular to neighborhood levels, on the incidence, aggressiveness, and survival of renal cell carcinoma (RCC). The research aims to unravel the...
This $113,147 federal Project Grant award was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to The Leland Stanford Junior University. The grant will fund a 5-year career development program for Dr. Chris McGinnis to prepare him for an independent research career in cancer immunology, focusing on studying tumor-immune interactions during metastasis. The key objectives are to: 1) Use longitudinal single-cell RNA sequencing to uncover novel mechanisms of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $931,841 to The Leland Stanford Junior University to develop next-generation immunotherapies for pediatric cancers. The funding will support research to overcome the suppressive tumor microenvironment in pediatric solid tumors, optimize multi-specific CAR T cells, and explore in vivo gene delivery approaches to engineer immune populations without ex vivo manufacturing. This work aims to...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to validate a novel preclinical mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test prevention agents. The $602,315 award to the University of Colorado-Denver will: Define the human relevance of the in vivo NTCU/cigarette smoke mouse model of lung SCC premalignant lesions. Validate an ex vivo precision cut lung slice...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the effects of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research aims to understand how NRF2 activation impacts LUSC initiation, progression, and the tumor microenvironment using a novel genetically-engineered mouse model. The University of Washington will perform multi-omics...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Federal Grant Program "Cancer Biology Research" (CFDA 93.396), provides $640,760 to The Leland Stanford Junior University to conduct comprehensive research on the fundamental biological mechanisms underlying pancreatic ductal adenocarcinoma (PDAC) metastasis, organ tropism, and immune evasion. The key products and services to be delivered through this 5-year project include: 1) employing molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding of $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel inhibitors of the NSMASE2 enzyme for enhancing the effectiveness of immune checkpoint inhibitors in cancer treatment. The project aims to synthesize and test PDDC analogs to improve the potency, solubility, and pharmacokinetics of NSMASE2 inhibitors. Promising...